Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Interest & Investment Income (2022 - 2026)

Axsome Therapeutics' Interest & Investment Income history spans 5 years, with the latest figure at -$1.2 million for Q1 2026.

  • On a quarterly basis, Interest & Investment Income rose 51.25% to -$1.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$5.3 million, a 32.92% increase, with the full-year FY2025 number at -$6.6 million, changed 0.18% from a year prior.
  • Interest & Investment Income hit -$1.2 million in Q1 2026 for Axsome Therapeutics, down from -$1.2 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for AXSM hit a ceiling of -$702000.0 in Q4 2023 and a floor of -$2.7 million in Q2 2023.
  • Historically, Interest & Investment Income has averaged -$1.7 million across 5 years, with a median of -$1.3 million in 2022.
  • Biggest five-year swings in Interest & Investment Income: skyrocketed 68.6% in 2023 and later plummeted 214.81% in 2024.
  • Tracing AXSM's Interest & Investment Income over 5 years: stood at -$1.3 million in 2022, then soared by 46.94% to -$702000.0 in 2023, then plummeted by 214.81% to -$2.2 million in 2024, then surged by 46.97% to -$1.2 million in 2025, then decreased by 1.11% to -$1.2 million in 2026.
  • Business Quant data shows Interest & Investment Income for AXSM at -$1.2 million in Q1 2026, -$1.2 million in Q4 2025, and -$1.1 million in Q3 2025.